The 29 portfolio companies we’ve helped build have attracted more than $2.3B of risk capital, employ close to 1,000 Canadians and have a combined value of $4B.
Our Portfolio Companies actively benefit from direct investment by adMare BioInnovations, showcasing our commitment to fostering innovative growth in the biotech sector.
Abdera Therapeutics Inc. is a precision oncology company focused on developing next-generation effective targeted alpha radiation therapies (TATs) for patients with relapsed, refractory and metastatic cancers.